The response to PD-1 blockade therapy is highly variable and the reasons for this variability remain unclear, but melanoma patients with melanoma who have a higher proportion of TCF-1+ CD8+ T cells showed a better response after PD-1 blockade and survived longer (26). This evidence concerns the gene PDCD1 and melanoma.